| Rx0000322 |
SA3, LLC |
12/31/2020 |
69420307701 |
Lidocaine/Tetracaine 7%/7% Cream (30g) |
10/23/2020 |
636.67 |
1075.00 |
01/14/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=465 |
Authorized Generic |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649040130 |
ANUSOl-HC? (Hydrocortisone Cream, USP) 2.5%, 30gm |
01/09/2020 |
8.00 |
141.31 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649041112 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 12 |
01/09/2020 |
35.61 |
629.18 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649041124 |
ANUSOl-HC® (Hydrocortisone Acetate Suppository, USP) 25mg, 24 |
01/09/2020 |
71.23 |
1258.40 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649024141 |
AZASAN? (Azathioprine Tablets, USP) 100mg, 100ct |
01/09/2020 |
44.85 |
792.43 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649023141 |
AZASAN? (Azathioprine Tablets, USP) 75mg, 100ct |
01/09/2020 |
100.61 |
1777.46 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649020175 |
MOVIPREP? (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate & Ascorbic Acid for Oral Solution), 1 Kit |
01/09/2020 |
6.34 |
112.03 |
09/01/2024 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649070141 |
OSMOPREP? (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) 1500mg Tablets, 100ct |
01/09/2020 |
41.22 |
728.15 |
06/22/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649065103 |
UCERIS? (budesonide) Rectal Aerosol, Foam, two 54 ml Canisters, 2 mg/actuation |
01/09/2020 |
37.65 |
665.18 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. No patent expiration date listed. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649030103 |
XIFAXAN? (rifaximin) 200mg Tablets, 30ct |
01/09/2020 |
49.08 |
670.36 |
07/24/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649030303 |
XIFAXAN? (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card |
01/09/2020 |
187.11 |
2555.59 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000095 |
Salix Pharmaceuticals, Inc. |
03/31/2020 |
65649030302 |
XIFAXAN? (rifaximin) 550mg Tablets, 60ct |
01/09/2020 |
187.11 |
2555.59 |
10/02/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000011 |
Sanofi |
03/31/2020 |
49281025051 |
IMOVAX single carton containing 1 single-dose Vial With 1 Single-dose Prefilled Syringe of diluent with the potency of one dose (1.0 mL) of Imovax Rabies vaccine is equal to or greater than 2.5 international units of rabies antigen. |
01/01/2020 |
17.82 |
374.17 |
None |
Innovator Multiple Source Drug |
None |
1 |
In 2017, Sanofi announced our progressive and industry-leading pricing principles to help stakeholders understand our pricing decisions and to advance a more informed discussion of issues related to the pricing of medicines. These principles include a pledge to keep annual list price increases at or below the projected U.S. National Health Expenditure (NHE) growth rate, an estimate of medical spending calculated by the Centers for Medicare and Medicaid Services (CMS) and often used as a measure of healthcare inflation. These principles apply to all of our prescription medicines if a pricing decision results in more than a $15 annual increase in the price of the medication. In addition, we committed to making both our average aggregate list and net price changes across our portfolio transparent to help illustrate how revenue accrues to Sanofi versus other parts of the pharmaceutical supply chain.
In determining our list price increases, we balance the rising demands by payors/intermediaries, and the increased costs of manufacturing and distribution of our products with the need to fund our pipeline while also working to limit the out of pocket burden on patients. Across our entire portfolio of medicines, the average aggregate list price increase was 2.9 percent while the average aggregate net price – that is, the actual price paid to Sanofi – declined by 11.1 percent.
Sanofi fully understands the affordability of our products is critical to patients. We are committed to helping patients get the treatment that they are prescribed by their healthcare professional.
We do not attribute a specific portion of the total list price increase to any one factor. Sanofi is committed to helping ensure patients can afford the treatments they are prescribed by their healthcare professional. |
None |
See response for cost increase factors |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank because the drug was not acquired within the previous 5 years |
| Rx0000092 |
Santarus, Inc. |
03/31/2020 |
68012025820 |
CYCLOSET (bromocriptine mesytate tablets) 0.8 mg tablets, 200 ct |
01/09/2020 |
50.32 |
889.06 |
04/30/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
| Rx0000035 |
Saol Therapeutics Inc |
03/31/2020 |
70504012602 |
VARIZIG, single dose vial, 125IU, 1.2mL vial |
03/01/2020 |
162.52 |
1804.14 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/28/2017 |
Aptevo Therapeutics Inc |
65000000 |
None |
65,000,000 upfront cost. 74,500,000 total value. Multiple products/ NDCs were part of the total acquisition. Varizig was one of the products acquired. |
1306.34 |
1256.10 |
2012 |
682.50 |
None |
Varizig was introduced to the market in 2012 as a lyophilized powder. The current formulation is liquid.
Products were acquired in September 2017. Scaling the manufacturing process to meet product demand was a costly process that contributed to the price increase. Other costly factors that contributed to the increase were: scaling supply chain capabilities to meet additional product overhead: shipping, stocking and distribution. Financial costs and debt incurred with acquiring the products and contract rights were also contributing factors.
Patent Exp. Date: N/A (Biologic drug status) |
| Rx0000086 |
Seattle Genetics, Inc. |
03/31/2020 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
01/01/2020 |
310.00 |
8270.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
(1) Seattle Genetics does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seattle Genetics limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seattle Genetics to insert only a year for this data field. As a result, Seattle Genetics has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seattle Genetics' patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seattle Genetics did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-U blank because they are not applicable to this product. |
| Rx0000086 |
Seattle Genetics, Inc. |
09/30/2020 |
51144005001 |
ADCETRIS, 50mg, single-dose vial, packaged singly |
07/01/2020 |
322.00 |
8592.00 |
12/31/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Office of Statewide Health Planning and Development's ("OSHPD") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to OSHPD, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-S blank because they are not applicable to this product. |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2020 |
71779011502 |
Copiktra 15 mg oral capsule, 56 capsules per package |
12/04/2020 |
1226.61 |
13616.61 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
12/31/2020 |
71779012502 |
Copiktra 25 mg oral capsule, 56 capsules per package |
12/04/2020 |
1226.61 |
13616.61 |
05/17/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/30/2020 |
Verastem, Inc. |
311000000 |
None |
None |
12390.00 |
11800.00 |
2018 |
11800.00 |
None |
None |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2020 |
00078065006 |
Farydak 10 mg capsule 6x blister pack |
03/23/2020 |
927.20 |
10687.18 |
09/30/2026 |
Single Source Drug |
None |
1 |
Secura Bio is required to spend millions of dollars on FDA and other agency required clinical trials and studies which results in the company losing money at the current price and sales volumes of Farydak. |
None |
No changes have been made to the product. |
None |
03/01/2019 |
Novartis |
None |
1 |
Disclosure of the acquisition price of Farydak from Novartis is restricted by non-disclosure provisions in the related legal agreements. |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
While Secura Bio, Inc. has been issued the labeler code 73116, Farydak product with this labeler code has not yet been introduced in the U.S. market. Current product being distributed in the U.S. market was produced by Novartis and accordingly is identified with Novartis' 00078 labeler code.
The Farydak product being supplied to the U.S. market currently is and will be produced by Novartis for the next couple of years under a supply agreement. We expect existing inventories with the Novartis labeler code to be sold for most of 2020. |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2020 |
00078065106 |
Farydak 15 mg capsule 6x blister pack |
03/23/2020 |
927.20 |
10687.18 |
09/30/2026 |
Single Source Drug |
None |
1 |
Secura Bio is required to spend millions of dollars on FDA and other agency required clinical trials and studies which results in the company losing money at the current price and sales volumes of Farydak. |
None |
No changes have been made to the product. |
None |
03/01/2019 |
Novartis |
None |
1 |
Disclosure of the acquisition price of Farydak from Novartis is restricted by non-disclosure provisions in the related legal agreements. |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
While Secura Bio, Inc. has been issued the labeler code 73116, Farydak product with this labeler code has not yet been introduced in the U.S. market. Current product being distributed in the U.S. market was produced by Novartis and accordingly is identified with Novartis' 00078 labeler code.
The Farydak product being supplied to the U.S. market currently is and will be produced by Novartis for the next couple of years under a supply agreement. We expect existing inventories with the Novartis labeler code to be sold for most of 2020. |
| Rx0000121 |
Secura Bio, Inc. |
03/31/2020 |
00078065206 |
Farydak 20 mg capsule 6x blister pack |
03/23/2020 |
927.20 |
10687.18 |
09/30/2026 |
Single Source Drug |
None |
1 |
Secura Bio is required to spend millions of dollars on FDA and other agency required clinical trials and studies which results in the company losing money at the current price and sales volumes of Farydak. |
None |
No changes have been made to the product. |
None |
03/01/2019 |
Novartis |
None |
1 |
Disclosure of the acquisition price of Farydak from Novartis is restricted by non-disclosure provisions in the related legal agreements. |
8139.93 |
8059.34 |
2015 |
6860.00 |
None |
While Secura Bio, Inc. has been issued the labeler code 73116, Farydak product with this labeler code has not yet been introduced in the U.S. market. Current product being distributed in the U.S. market was produced by Novartis and accordingly is identified with Novartis' 00078 labeler code.
The Farydak product being supplied to the U.S. market currently is and will be produced by Novartis for the next couple of years under a supply agreement. We expect existing inventories with the Novartis labeler code to be sold for most of 2020. |
| Rx0000028 |
Servier Pharmaceuticals LLC |
03/31/2020 |
72694095401 |
Oncaspar 750 IU/mL injection, 5 mL single use vial |
01/02/2020 |
1590.52 |
18601.38 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/31/2018 |
Shire |
None |
1 |
None |
14544.54 |
14544.54 |
1994 |
1.00 |
None |
Note, the value of "$1.00" is a placeholder, because the system would not allow an empty field. The placeholder was necessary because the WAC at introduction is unknown to Servier.
Servier acquired Shire's oncology business on August 31, 2018 and the BLA for Oncaspar (NDC 00944381001) was transferred to Servier in August 2019.
At the time of Servier's 60-day notice of price increase, Servier was selling product labeled with the 00944381001 NDC (the NDC/label used by Shire). The vials with this NDC are now sold out and the Shire NDC should be made obsolete. Since the 60-day notice of price increase, Servier obtained its own NDC (72694095401) for Oncaspar and began selling Servier labeled Oncaspar on 4/1/2020. |
| Rx0000028 |
Servier Pharmaceuticals LLC |
03/31/2020 |
00944381001 |
Oncaspar 750 IU/mL injection, 5 mL single-use vial |
01/02/2020 |
1590.52 |
18601.38 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/31/2018 |
Shire |
None |
1 |
None |
14544.54 |
14544.54 |
1994 |
1.00 |
None |
Note, the value of "$1.00" is a placeholder, because the system would not allow an empty field. The placeholder was necessary because the WAC at introduction is unknown to Servier.
Servier acquired Shire's oncology business on August 31, 2018 and the BLA for Oncaspar (NDC 00944381001) was transferred to Servier in August 2019. |
| Rx0000004 |
Shionogi Inc. |
03/31/2020 |
59630058090 |
Osphena (ospemifene) 60MG Tablets |
01/01/2020 |
32.40 |
680.40 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Osphena was developed by Shionogi. The pricing at launch was $474.00 |
| Rx0000175 |
Sobi Inc |
03/31/2020 |
66658011203 |
Kepivance-lyophilized powder containing 6.25 mg of Palifermin. - 3-pack |
01/01/2020 |
414.66 |
8093.62 |
04/11/2023 |
Single Source Drug |
176 |
None |
acquiring/producing/shipping goods. |
None |
acquiring/producing/shipping goods. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
we did not acquire this drug within the last five years |
| Rx0000175 |
Sobi Inc |
03/31/2020 |
66658011206 |
Kepivance-lyophilized powder containing 6.25 mg of Palifermin. - 6-pack |
01/01/2020 |
829.33 |
16187.26 |
04/11/2023 |
Single Source Drug |
441 |
None |
acquiring/producing/shipping goods. |
None |
acquiring/producing/shipping goods. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
we did not acquire this drug within the last five years |
| Rx0000175 |
Sobi Inc |
03/31/2020 |
66658023407 |
Kineret- Single-use 100 mg prefilled syringe -7-pack |
01/01/2020 |
55.59 |
1085.06 |
07/29/2020 |
Single Source Drug |
6461 |
None |
acquiring/producing/shipping goods. |
None |
acquiring/producing/shipping goods. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
we did not acquire this drug within the last five years |
| Rx0000244 |
Sprout Pharmaceuticals, Inc. |
03/31/2020 |
58604021430 |
Addyi 100 mg tablets 30-count bottle |
01/01/2020 |
37.50 |
437.50 |
05/09/2023 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000221 |
Strides Pharma, Inc. |
09/30/2020 |
64380072006 |
Tacrolimus Capsules 0.5mg, 100 |
09/14/2020 |
18.68 |
55.56 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement have been made |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
#6:No patent expiration date listed; #8 and #10 are left blank because these are confidential, trade secret information of Strides Pharma Inc. ("Strides") that would cause competitive harm to Strides if publicly disclosed because: (1) Strides uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Strides' ability to negotiate terms of such contracts; (2) Strides competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Strides production cost, other product costs, and profit margin, it will prejudice Strides' ability to competitively price its products. For these reasons, Strides requests protection of the information of this submission from public disclosure; #14-22: This product was developed by Strides and therefore the acquisition sections are left blank |
| Rx0000221 |
Strides Pharma, Inc. |
09/30/2020 |
64380072206 |
Tacrolimus Capsules 5mg, 100 |
09/14/2020 |
201.40 |
555.55 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
No change or improvement have been made |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
#6:No patent expiration date listed; #8 and #10 are left blank because these are confidential, trade secret information of Strides Pharma Inc. ("Strides") that would cause competitive harm to Strides if publicly disclosed because: (1) Strides uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Strides' ability to negotiate terms of such contracts; (2) Strides competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Strides production cost, other product costs, and profit margin, it will prejudice Strides' ability to competitively price its products. For these reasons, Strides requests protection of the information of this submission from public disclosure; #14-22: This product was developed by Strides and therefore the acquisition sections are left blank |
| Rx0000149 |
Strongbridge Biopharma plc |
03/31/2020 |
71090000101 |
Keveyis (dichlorphenamide) oral tablet, 50mg, Bottle of 100 |
01/06/2020 |
1706.57 |
20668.38 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
12/12/2016 |
Taro Pharmaceuticals Industries |
8500000 |
None |
None |
13650.00 |
13650.00 |
2015 |
13650.00 |
None |
None |
| Rx0000001 |
SUN PHARMACEUTICALS |
03/31/2020 |
47335030383 |
Odomzo Oral Capsule 200 MG/ Pkg 30 |
03/01/2020 |
565.17 |
11868.59 |
09/15/2029 |
Single Source Drug |
None |
1 |
The increase to the WAC is intended to offset the cost of higher discounts and rebates offered to higher volume customers |
None |
No change or improvement have been made |
None |
01/27/2017 |
Novartis Pharmaceutical |
None |
1 |
Confidential: Odomzo was purchased from Novartis for $175M. |
10060.00 |
10060.00 |
2017 |
10060.00 |
None |
This report includes confidential, trade secret information of Sun Pharmaceutical Industries, Inc. (Sun) that would cause competitive harm to Sun if publicly disclosed because: (1) Sun uses this information when it negotiates sales contracts for the product and if customers have this data, it may prejudice Sun's ability to negotiate terms of such contracts; (2) Sun competes with other companies in the sale of drugs based on pricing and other factors; thus, if competitors have access to data about Sun's production cost, other product costs, and profit margin, it will prejudice Sun's ability to competitively price its products. For these reasons, Sun requests protection of the information of this submission from public disclosure, pursuant to the Defend Trade Secret Act (DTSA), Pub.L. 114–153, 130 Stat. 376, 18 U.S.C. § 1836, et seq. The reason this information is protected from misappropriation and disclosure under the DTSA is because such constitutes information that Sun treats as secret, takes steps to keep secret, and which has independent economic value from not being generally known nor readily ascertainable. |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772012101 |
Oxtellar XR, 150mg Capsule, 100CT |
01/01/2020 |
52.98 |
715.19 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772012201 |
Oxtellar XR, 300mg Capsule, 100CT |
01/01/2020 |
73.60 |
993.59 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772012301 |
Oxtellar XR, 600mg Capsule, 100CT |
01/01/2020 |
134.75 |
1819.17 |
04/13/2027 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010301 |
Trokendi XR, 100mg Capsule, 100CT |
01/01/2020 |
197.37 |
2664.55 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010330 |
Trokendi XR, 100mg Capsule, 30 CT |
01/01/2020 |
59.21 |
799.36 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010315 |
Trokendi XR, 100mg Capsule, 30 CT Blister Pack |
01/01/2020 |
59.21 |
799.36 |
04/04/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010401 |
Trokendi XR, 200mg Capsule, 100CT |
01/01/2020 |
269.99 |
3644.91 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010430 |
Trokendi XR, 200mg Capsule, 30 CT |
01/01/2020 |
81.00 |
1093.48 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010415 |
Trokendi XR, 200mg Capsule, 30 CT Blister Pack |
01/01/2020 |
81.00 |
1093.48 |
04/04/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010101 |
Trokendi XR, 25mg Capsule, 100 CT |
01/01/2020 |
76.48 |
1032.43 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010130 |
Trokendi XR, 25mg Capsule, 30 CT |
01/01/2020 |
22.94 |
309.73 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010115 |
Trokendi XR, 25mg Capsule, 30 CT Blister Pack |
01/01/2020 |
22.94 |
309.73 |
04/04/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010201 |
Trokendi XR, 50mg Capsule, 100CT |
01/01/2020 |
99.62 |
1344.85 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010230 |
Trokendi XR, 50mg Capsule, 30 CT |
01/01/2020 |
29.88 |
403.44 |
04/04/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
03/31/2020 |
17772010215 |
Trokendi XR, 50mg Capsule, 30 CT Blister Pack |
01/01/2020 |
29.88 |
403.44 |
04/04/2028 |
Single Source Drug |
0 |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
12/31/2020 |
27505011130 |
Xadago, 100 mg, 30 CT |
10/01/2020 |
65.45 |
904.56 |
12/10/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
None |
839.11 |
780.57 |
2017 |
730.19 |
None |
None |
| Rx0000165 |
Supernus Pharmaceuticals, Inc. |
12/31/2020 |
27505011030 |
Xadago, 50mg, 30 CT |
10/01/2020 |
65.45 |
904.56 |
12/10/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
06/09/2020 |
US Worldmeds |
None |
1 |
None |
839.11 |
780.57 |
2017 |
730.19 |
None |
None |